AssetMark Inc
FLGT icon

AssetMark Inc’s Fulgent Genetics FLGT Stock Holding History

AssetMark Inc’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-8
Closed -$157 – 2295
2024
Q2 		$157 Hold
8
– – ﹤0.01% 2021
2024
Q1 		$174 Sell
8
-127
-94% -$3.15K ﹤0.01% 1796
2023
Q4 		$3.9K Sell
135
-19,154
-99% -$512K ﹤0.01% 1475
2023
Q3 		$516K Sell
19,289
-747
-4% -$25.5K ﹤0.01% 753
2023
Q2 		$742K Buy
20,036
+1,565
+8% +$54.6K ﹤0.01% 659
2023
Q1 		$577K Buy
18,471
+9,403
+104% +$303K ﹤0.01% 691
2022
Q4 		$270K Sell
9,068
-6,646
-42% -$238K ﹤0.01% 783
2022
Q3 		$599K Buy
15,714
+615
+4% +$30.8K ﹤0.01% 624
2022
Q2 		$823K Buy
15,099
+1,449
+11% +$79.6K ﹤0.01% 542
2022
Q1 		$852K Buy
13,650
+229
+2% +$15.1K ﹤0.01% 504
2021
Q4 		$1.35M Buy
13,421
+361
+3% +$31.7K 0.01% 371
2021
Q3 		$1.18M Buy
13,060
+12,997
+20,630% +$1.18M 0.01% 379
2021
Q2 		$6K Buy
+63
New +$5.03K ﹤0.01% 1044

Other funds holding FLGT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AssetMark Inc's FLGT Position: Q3 2024 in Review

AssetMark Inc sold out of Fulgent Genetics (FLGT) in Q3 2024, closing a stake of 8 shares — an estimated $157 sold.

AssetMark Inc first reported a position in FLGT in Q2 2021 and held it in 13 quarters. The position peaked at $1.35M in Q4 2021. 183 funds tracked by Wall St. Rank hold FLGT as of Q3 2024.

  • AssetMark Inc reported no remaining Fulgent Genetics position as of Q3 2024 after selling out during the quarter.
  • AssetMark Inc sold 8 Fulgent Genetics shares in Q3 2024, an estimated $157.
  • AssetMark Inc first reported a position in Fulgent Genetics in Q2 2021 and held it in 13 quarters.
  • AssetMark Inc's Fulgent Genetics position peaked at $1.35M in Q4 2021.
  • 183 funds tracked by Wall St. Rank held Fulgent Genetics as of Q3 2024.

Based on AssetMark Inc's 13F filing for Q3 2024, filed 1 Nov 2024.